OVERVIEW

Advances in Inflammatory Bowel Diseases 2018 - Clinical Track is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Dec 21, 2018 - Dec 21, 2019.

Accreditation:
CME
Physicians
Imedex Designates This Live Activity For A Maximum Of 11.50 Ama Pra Category 1 Credits™.
Physicians Should Claim Only The Credit Commensurate With The Extent Of Their Participation In The Activity.

Physician Assistants
NACCME Has Been Authorized By The American Academy Of Pas (Aapa) To Award Aapa Category 1 CME Credit For Activities Planned In Accordance With The Aapa Cme Criteria. This Activity Is Designated For 11.50 Aapa Category 1 Credits.

CNE
This Continuing Nursing Education Activity Awards 11.50 Contact Hours.
Provider Approved By The California Board Of Registered Nursing, Provider #13255 For 11.50 Contact Hours.

CPE
This Knowledge-based Activity (Ja0006201-9999-18-249-h01-p) Is Approved For 11.50 Contact Hours (1.15 Ceus) Of Continuing Pharmacy Education.

Target Audience
This Educational Activity Is Designed For Gastroenterologists And Other Healthcare Professionals (Physicians-in-training, Nurses, Pharmacists, Physician Assistants, Etc) Involved And/or Interested In The Therapeutic Management Of Patients With Ibd.

Overview
The Therapeutic Landscape Of Ibd Has Evolved Significantly Over Recent Years, And New Medication Approvals, Biosimilar Approvals, And Other Potential Targeted Therapies For Ibd Are Emerging At A Rapid Pace. These Novel Therapies Have Led To Significant Improvements In The Clinical Management Of Ibd And Have Led To Recommendations For Earlier Diagnosis And Personalized Treatment. With These Rapid Advances, Clinicians Are Challenged To Critically Assess Emerging Data And To Implement Safe And Effective Solutions For Current Clinical Challenges. Clinicians Need Expert Guidance To Help Them Integrate New And Promising Data Into Their Clinical Practices.

Objectives:
Upon Successful Completion Of This Educational Activity, Participants Should Be Better Able To:
• Offer Rationales For The Positioning Of Therapies In Emerging Drug Classes, Including Lymphocyte Trafficking Inhibitors, Il-12/23 Inhibitors, And Jak Inhibitors
• Summarize Acg Guidelines For The Treatment Of Severe Crohn’s Disease And Ulcerative Colitis
• Employ Strategies To Optimally Manage Opportunistic Infections In Ibd, Including CClostridiumDifficile And Other Bacteria, Viruses, And Fungal Complications
• Describe Considerations For De-escalating, Restarting, And Switching Biologic Therapies
• Discuss Issues Of Interest With Women With Ibd Who Are Of Childbearing Age, Such As Sexual Dysfunction, Infertility, And Continuing Ibd Therapy While Pregnant
• Outline Strategies For The Prevention Of Post-operative Recurrence Of Crohn’s Disease
• Describe Management Considerations For Complex Ibd Cases Involving Malignanc